Synapse February 2013 focuses on injunctions against pharma patent infringement
In Synapse February 2013, Taylor Wessing discusses the issue of interim injunctions against pharmaceutical patent infringement. Synapse focuses on law for the life sciences industry.
The patent system gives innovators a monopoly right — a right that in the life science and pharmaceutical sector can be extremely valuable. It is perhaps unsurprising therefore that a manufacturer will go to some lengths to enforce their patent rights protecting a product.
A powerful tool for this purpose is the injunction, which — if deployed correctly — can stop a potential infringer in their tracks.
Other topics covered in Synapse February 2013 include: the Transparency Directive and the customs regulation.
To read more click here.
News from Taylor Wessing
News from The Lawyer
Briefings from Taylor Wessing
The Court of Appeal has allowed Novartis’s application for a preliminary injunction against Hospira.
This guide shares the key trends that Taylor Wessing is seeing in the UK consumer products sector.
Analysis from The Lawyer
Financial disputes are starting to dominate the English courts as the long-awaited fallout from the downturn finally comes to town
A single patent court system for Europe and the high-profile ‘phone wars’ are putting IP at the heart of clients’ business strategies